Ask Anything
ESC 2026 DiscussionExplore the Hot Line trials, expert perspectives, and key takeawaysExplore the discussion→Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
Guideline5 mentionsExpert CommentaryAHA Professional Heart Daily Highlight
SEP 15ContrerasCirculation
State of Cardiovascular Disease and Stroke in Hispanic/Latino Adults in the United States: A Scientific Statement From the American Heart Association
Mandates heritage-specific screening and interventions for Hispanic adults; challenges the Hispanic paradox as an oversimplification requiring disaggregated data.
RCT · n=17,6044 mentionsMedscape Cardiology Highlight
SEP 16OstrominskiJAMA Cardiology
Semaglutide consistently reduces major cardiovascular events across all frailty categories.
Supports semaglutide use across frailty levels in CVD; extends SELECT benefits to frail subgroups without heterogeneity.
MCMedscape Cardiology
What was less expected was that persons with frailty appeared to derive greater benefits on how they felt and functioned (eg, mobility appeared to improve more with semaglutide in persons with frailty); and that, compared with placebo, persons with greater frailty were actually less likely to dis...
RCT1 mentions
SEP 14ZhaoCirculation
Response by Zhao et al to Letter Regarding Article, “Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial”
Correspondence response addresses inquiries regarding dapagliflozin for recurrence after catheter ablation, highlighting methodological considerations.
ZZZixu Zhao
Cardiovascular electrophysiology fellow, Beijing Anzhen Hospital
It is not a problem to use dapagliflozin, but we did not see any effect on early recurrence of AFib. However, we remain very confident about its potential, given that a considerable proportion of patients with atrial fibrillation also have heart failure, particularly heart failure with preserved ejection fraction. We believe that a larger, placebo-controlled trial with an extended follow-up period is warranted to more comprehensively evaluate its potential antiarrhythmic benefits.
RCT · n=1001 mentionsTrending on X
SEP 15HuangEducational Gerontology
Video-based education shows no benefit over nurse-guided pamphlets for home BP knowledge or skills.
Video-based education matches nurse-guided pamphlets for home BP skills in stage 3–4 CKD; supports equivalent efficacy of scalable digital versus traditional education.
RCT1 mentions
SEP 14VoorhoutNetherlands Heart Journal
DUTCH-WAIST tests whether semaglutide plus lifestyle intervention improves rhythm control in persistent AF.
DUTCH-WAIST will test semaglutide for rhythm control in overweight persistent AF; leaves open whether GLP-1 RAs improve arrhythmia outcomes pending RCT results.
cohort · n=1,0411 mentionsTrending on X
SEP 15UedaESC Heart Failure
Age ≥70 years is linked to ~9-fold higher mortality in COVID-19 vaccine-related myocarditis.
May warrant closer monitoring in elderly patients with vaccine myocarditis; hypothesis-generating and requires prospective confirmation.
cohort · n=469
SEP 14PiedimonteCirculation Cardiovascular Interventions
Minicrush links to comparable TLF versus TAP but ~86% lower stent thrombosis.
Minicrush was associated with lower stent thrombosis than TAP without differing target lesion failure; leaves open need for randomized confirmation in bifurcation PCI.
RCT
SEP 14XuCirculation
Letter by Xu et al Regarding Article, “Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial”
Correspondence analyzes early recurrence outcomes after catheter ablation for atrial fibrillation with dapagliflozin, highlighting key methodological considerations in trial interpretation.
Guideline · n=23
SEP 14McBeathEuropean Heart Journal - Digital Health
Patient and clinician perspectives on digital tools in heart failure: results in three London hospital networks (Qual-HF)
Clinicians should assess digital literacy and offer guided resources; leaves open development of evidence-based guidelines for heart failure digital tools.
cohort · n=1,802,9202 mentionsTrending on X
SEP 15IhenetuJournal of Medical Internet Research
Machine-learning model for hypertension case-finding yields ~63% sensitivity and low positive predictive value.
Modest sensitivity, low PPV, and demographic biases caution against clinical use; leaves open whether complex ML outperforms simpler regression for hypertension case-finding.
